ATE340593T1 - Ermittlung der auswirkung von einem clostridial toxin auf muskeln - Google Patents

Ermittlung der auswirkung von einem clostridial toxin auf muskeln

Info

Publication number
ATE340593T1
ATE340593T1 AT03721336T AT03721336T ATE340593T1 AT E340593 T1 ATE340593 T1 AT E340593T1 AT 03721336 T AT03721336 T AT 03721336T AT 03721336 T AT03721336 T AT 03721336T AT E340593 T1 ATE340593 T1 AT E340593T1
Authority
AT
Austria
Prior art keywords
clostridial toxin
muscles
determining
effects
muscle
Prior art date
Application number
AT03721336T
Other languages
English (en)
Inventor
Lisa D Hanin
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28039639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340593(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE340593T1 publication Critical patent/ATE340593T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03721336T 2002-03-14 2003-03-07 Ermittlung der auswirkung von einem clostridial toxin auf muskeln ATE340593T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/099,602 US6688311B2 (en) 2002-03-14 2002-03-14 Method for determining effect of a clostridial toxin upon a muscle

Publications (1)

Publication Number Publication Date
ATE340593T1 true ATE340593T1 (de) 2006-10-15

Family

ID=28039639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03721336T ATE340593T1 (de) 2002-03-14 2003-03-07 Ermittlung der auswirkung von einem clostridial toxin auf muskeln

Country Status (10)

Country Link
US (2) US6688311B2 (de)
EP (1) EP1482986B1 (de)
JP (3) JP2005520826A (de)
KR (1) KR100963798B1 (de)
AT (1) ATE340593T1 (de)
AU (1) AU2003224657A1 (de)
CA (1) CA2478762A1 (de)
DE (1) DE60308654T2 (de)
ES (1) ES2272975T3 (de)
WO (1) WO2003077954A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
BRPI0411346A (pt) * 2003-06-12 2006-07-11 Control Bionics método, sistema e software para comunicação interativa e análise
US7101742B2 (en) 2003-08-12 2006-09-05 Taiwan Semiconductor Manufacturing Company, Ltd. Strained channel complementary field-effect transistors and methods of manufacture
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
RU2257914C1 (ru) * 2004-03-31 2005-08-10 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства Здравоохранения Российской Федерации Способ лечения паралитического косоглазия
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US8996603B2 (en) * 2004-09-16 2015-03-31 Cisco Technology, Inc. Method and apparatus for user domain based white lists
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
SG160357A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20060276720A1 (en) * 2005-06-03 2006-12-07 Mcginnis William C Method of using dermatomal somatosensory evoked potentials in real-time for surgical and clinical management
JP4763347B2 (ja) * 2005-06-03 2011-08-31 ポーラ化成工業株式会社 マッサージ方法又はマッサージ料の評価方法
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
BRPI0613631A8 (pt) * 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7593769B1 (en) * 2006-02-14 2009-09-22 Iq Biolabs, Inc. Surface electromyography index
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
MX379265B (es) * 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
DE102008032021A1 (de) * 2008-07-07 2010-01-21 Proebstle, Thomas, Dr. Verfahren zum quantitativen Analysieren der Wirkung eines Effektors auf die mit Muskelkontraktion assoziierte Motilität der Haut
US8126542B2 (en) * 2008-12-10 2012-02-28 Somaxis, Inc. Methods for performing physiological stress tests
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
RU2458627C1 (ru) * 2011-04-05 2012-08-20 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Способ количественной оценки спастичности при центральном парезе
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
WO2013112974A1 (en) * 2012-01-27 2013-08-01 Revance Therapeutics, Inc. Methods and assessment scales for measuring wrinkle severity
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
JP2019122655A (ja) * 2018-01-18 2019-07-25 パシフィックメディコ株式会社 筋電位取得装置
US11752335B1 (en) 2018-02-07 2023-09-12 Mary Kay Inc. Method for determining facial muscle responses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689668A (en) * 1967-10-18 1972-09-05 Emile Leon Piette Method of alleviating wrinkles on skin
FR2589242B1 (fr) * 1985-10-25 1988-11-25 Oreal Procede pour examiner la surface d'un echantillon et appareil pour sa mise en oeuvre
AT391998B (de) * 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
GB8806737D0 (en) * 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5211894A (en) * 1990-10-09 1993-05-18 Amway Corporation Skin replication technique
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US5898545A (en) * 1997-07-01 1999-04-27 International Business Machines Corporation Head load/unload and disk airflow control apparatus
EP1011695B2 (de) 1997-07-15 2009-11-04 The Regents of the University of Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
EP1128844B1 (de) 1998-10-27 2006-01-04 Mayo Foundation For Medical Education And Research Botulinumtoxine zur verstärkung der wundheilung
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
ES2320849T3 (es) 1999-04-16 2009-05-29 Marvin Schwartz Procedimiento para reducir la perdida del cabello y estimular el crecimiento del mismo.
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle

Also Published As

Publication number Publication date
JP2010106026A (ja) 2010-05-13
KR100963798B1 (ko) 2010-06-17
JP2005520826A (ja) 2005-07-14
CA2478762A1 (en) 2003-09-25
US6688311B2 (en) 2004-02-10
US20040060569A1 (en) 2004-04-01
WO2003077954A1 (en) 2003-09-25
DE60308654T2 (de) 2007-08-23
AU2003224657A1 (en) 2003-09-29
KR20040093145A (ko) 2004-11-04
DE60308654D1 (de) 2006-11-09
EP1482986B1 (de) 2006-09-27
US7234469B2 (en) 2007-06-26
EP1482986A1 (de) 2004-12-08
ES2272975T3 (es) 2007-05-01
JP2013144711A (ja) 2013-07-25
US20030178029A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
ATE340593T1 (de) Ermittlung der auswirkung von einem clostridial toxin auf muskeln
ATE476719T1 (de) Verhaltensbasierte anpassung von computersystemen
DE60132931D1 (de) Zugriffs- und benutzungsmethoden für webseiten
WO2006033800A3 (en) System and method of automaticallymodifying an online dating service search using compatibility feedback
AU2003275359A1 (en) System and method for risk detection and analysis in a computer network
EA200300362A1 (ru) Способ генерирования молекулярно-функциональной сети
TW200517923A (en) Improved portrayal of navigation objects
BR9506217A (pt) Processo para identificação de estradas manuscritas e processo para determinar se dois segmentos contínuos pertencem a entradas manuscritas separadas
ATE212661T1 (de) Durch enzymkatalyse erhaltene therapeutische substanzen.
ATE433124T1 (de) System und verfahren zum analysieren von radarinformationen
NO20040193L (no) Stabilisert kraftforsyningssystem og fremgangsmate til drift av samme, samt dataprogram
DE602007008805D1 (de) Verbindungsanpassung in Abhängigkeit von der Kontrollsignalisierung
AU5804100A (en) Neuronal network for computer-assisted knowledge management
NO20032944D0 (no) Styringssystem for kjemisk injisering samt fremgangsmåte for kjemisk injisering i flere brönner
ATE426858T1 (de) System und verfahren zum erkennen von bísartigem code
ATE447174T1 (de) Verfahren zum direkten nachweis einzelner methotrexatmetabolite
ATE507524T1 (de) Durchführung von prüfungen an der betriebsmittelbenutzung von computerprogrammen
Blatner Morenean approaches: Recognizing psychodrama's many facets
ATE514245T1 (de) Verfahren und vorrichtung zur bestimmung von verwürfelungscodes für die signalübertragung
WO2005048108A3 (en) System, method, and computer program product for testing program code
FR2846252B1 (fr) Procede et dispositif de chromatographie integrant une etape de concentration
ATE363705T1 (de) Verfahren und system zum ermitteln der fortbewegungszeit einer mobilen nutzer- endeinrichtung
DE69737769D1 (de) Molekülmodell für vla-4-inhibitoren
DE60336097D1 (de) Verfahren zum Sammeln von Marktforschungsdaten
WO2005002414A3 (en) Prognosis determination in ewing sarcoma patients by means of genetic profiling

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties